Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333902 | 1.00 | MAOA (0.53) | MAOAKDM4EALDH1A1GAAHPGD | |
| SCHEMBL4323784 | 0.83 | MAOA (0.45) | MAOAKDM4EGAALMNASMN1; SMN2 | |
| SCHEMBL4323781 | 0.83 | MAOA (0.45) | MAOAKDM4EGAALMNASMN1; SMN2 | |
| SCHEMBL4338617 | 0.82 | MAOA (0.44) | MAOAKDM4EGAALMNASMN1; SMN2 | |
| SCHEMBL4338613 | 0.82 | MAOA (0.44) | MAOAKDM4EGAALMNASMN1; SMN2 | |
| SCHEMBL4334373 | 0.82 | ALDH1A1 (0.47) | MAOAKDM4EALDH1A1GAAHPGD | |
| SCHEMBL4334369 | 0.82 | ALDH1A1 (0.47) | MAOAKDM4EALDH1A1GAAHPGD | |
| SCHEMBL4338782 | 0.82 | ALDH1A1 (0.39) | MAOAKDM4EALDH1A1GAAHPGD | |
| SCHEMBL4330713 | 0.82 | MAOA (0.45) | MAOAKDM4EGAALMNASMN1; SMN2 | |
| SCHEMBL4330709 | 0.82 | MAOA (0.45) | MAOAKDM4EGAALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7521062-B2 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | MAOA 4418/4885KDM4E 3010/4885ALDH1A1 1459/4885 |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | MAOA 4455/4885KDM4E 2338/4885ALDH1A1 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.